Filspari Granted Accelerated Approval to Reduce Proteinuria in IgA Nephropathy
Sparsentan is an endothelin and angiotensin II receptor antagonist.
Sparsentan is an endothelin and angiotensin II receptor antagonist.
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The approval was based on data from the phase 3 ILLUMINATE-C study that included 21 dialysis-independent and -dependent patients with PH1.
The Company is currently evaluating OCE-205 in a phase 2 trial in adults who have developed hepatorenal syndrome with acute kidney injury.
The Bodyport Cardiac Scale is designed to detect signals through an individual’s feet to noninvasively measure a broad spectrum of hemodynamic biomarkers for heart function and fluid status.
In the CRL, the FDA stated that a satisfactory inspection is required before the NDA can be approved.
Researchers detected differential proteins in the plasma of patients with gout, patients with gout with kidney damage, and individuals without gout.
Although chronic kidney disease (CKD) is among the more common kidney ailments, patients may not be well-versed in its symptoms or complications. What should patients know about CKD, and how should healthcare providers be educating them?
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.